Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jul;97(3):657–668. doi: 10.1111/j.1476-5381.1989.tb12001.x

Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.

R A Armstrong 1, R A Lawrence 1, R L Jones 1, N H Wilson 1, A Collier 1
PMCID: PMC1854572  PMID: 2474350

Abstract

1. This study describes attempts to compare prostacyclin (IP-) receptors in human, pig, horse, rabbit and rat platelets and in circular muscle of human, rabbit and dog mesenteric and pig gastroepiploic arteries. Three stable prostacyclin analogues, iloprost, cicaprost and 6a-carba-prostacyclin (6a-carba-PGI2) and a prostaglandin endoperoxide analogue EP 157 (previously shown to mimic prostacyclin on human platelets) were used. 2. Our main conclusion is that prostacyclin receptors on human, pig and horse platelets are similar in nature, but distinct from those on rabbit and rat platelets. Functional studies (inhibition of aggregation) showed that iloprost and cicaprost always had similar potencies whereas 6a-carba PGI2 was much more potent than EP 157 on rabbit and rat platelets (300 and 1000 fold on a molar basis) compared with human, pig and horse platelets (2, 7 and 7 fold respectively). Measurement of initial rates of cyclic AMP production confirmed these orders of potency. 3. Although pig platelets were quite sensitive to inhibition by EP 157 (threshold = 10 nM in some experiments), maximal inhibition of aggregation was not always achieved (20 microM). EP 157 also produced only small elevations of cyclic AMP and inhibited rises in cyclic AMP induced by iloprost. It is possible that EP 157 has a lower efficacy than iloprost at the IP-receptor and on pig platelets it can sometimes act as a partial agonist. 4. Human, pig and horse platelet membranes bound [3H]-iloprost at 30 degrees C and this binding was inhibited by the four prostanoids. On human and pig membranes the order of potency was cicaprost = iloprost greater than 6a-carba PGI2 greater than EP 157. The order of potency may be similar on horse platelet membranes, but the analysis is complicated by the presence of a second component of [3H]-iloprost binding that is inhibited by iloprost and 6a-carba PGI2 but not by cicaprost. This binding may be due to the presence of an EP1-receptor, since iloprost and 6a-carba PGI2 but not cicaprost are known to have potent EP1-receptor agonist actions on smooth muscle preparations. IC50 values for cicaprost inhibition on human, pig and horse membranes were 110, 90 and 165 nM respectively. The need for IP-receptor radioligands of greater specificity is apparent from these studies. 5. Minimal binding of [3H]-iloprost to rabbit and rat platelet membranes was obtained at 30 degrees C.(ABSTRACT TRUNCATED AT 400 WORDS)

Full text

PDF
657

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aristoff P. A. Synthesis of prostacyclin analogs. Adv Prostaglandin Thromboxane Leukot Res. 1985;14:309–392. [PubMed] [Google Scholar]
  2. Armstrong R. A., Jones R. L., MacDermot J., Wilson N. H. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol. 1986 Mar;87(3):543–551. doi: 10.1111/j.1476-5381.1986.tb10196.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Armstrong R. A., Jones R. L., Peesapati V., Will S. G., Wilson N. H. Competitive antagonism at thromboxane receptors in human platelets. Br J Pharmacol. 1985 Mar;84(3):595–607. doi: 10.1111/j.1476-5381.1985.tb16139.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Armstrong R. A., Jones R. L., Wilson N. H. Mechanism of the inhibition of platelet aggregation produced by prostaglandin F2 alpha. Prostaglandins. 1985 Apr;29(4):601–610. doi: 10.1016/0090-6980(85)90083-8. [DOI] [PubMed] [Google Scholar]
  5. Corsini A., Folco G. C., Fumagalli R., Nicosia S., Noe M. A., Oliva D. (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol. 1987 Jan;90(1):255–261. doi: 10.1111/j.1476-5381.1987.tb16847.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Deguchi T., Saito M., Kono M. Blockade by N-methylhydroxylamine of activation of guanylate cyclase and elevations of guanosine 3',5'-monophosphate levels in nervous tissues. Biochim Biophys Acta. 1978 Nov 15;544(1):8–19. doi: 10.1016/0304-4165(78)90204-0. [DOI] [PubMed] [Google Scholar]
  7. Dong Y. J., Jones R. L. Effects of prostaglandins and thromboxane analogues on bullock and dog iris sphincter preparations. Br J Pharmacol. 1982 May;76(1):149–155. doi: 10.1111/j.1476-5381.1982.tb09200.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dong Y. J., Jones R. L., Wilson N. H. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol. 1986 Jan;87(1):97–107. doi: 10.1111/j.1476-5381.1986.tb10161.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fassina G., Froldi G., Caparrotta L. A stable isosterically modified prostacyclin analogue, FCE-22176, acting as a competitive antagonist to prostacyclin in guinea-pig trachea and atria. Eur J Pharmacol. 1985 Jul 31;113(3):459–460. doi: 10.1016/0014-2999(85)90097-4. [DOI] [PubMed] [Google Scholar]
  10. Gorman R. R., Bunting S., Miller O. V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins. 1977 Mar;13(3):377–388. doi: 10.1016/0090-6980(77)90018-1. [DOI] [PubMed] [Google Scholar]
  11. Hall J. M., Strange P. G. The use of a prostacyclin analogue, [3H]iloprost, for studying prostacyclin-binding sites on human platelets and neuronal hybrid cells. Biosci Rep. 1984 Nov;4(11):941–948. doi: 10.1007/BF01116892. [DOI] [PubMed] [Google Scholar]
  12. Harris D. N., Asaad M. M., Phillips M. B., Goldenberg H. J., Antonaccio M. J. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J Cyclic Nucleotide Res. 1979;5(2):125–134. [PubMed] [Google Scholar]
  13. Kennedy I., Coleman R. A., Humphrey P. P., Lumley P. Studies on the characterization of prostanoid receptors. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:327–332. [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Rodan G. A., Feinstein M. B. Interrelationships between Ca2+ and adenylate and guanylate cyclases in the control of platelet secretion and aggregation. Proc Natl Acad Sci U S A. 1976 Jun;73(6):1829–1833. doi: 10.1073/pnas.73.6.1829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rücker W., Schrör K. Evidence for high affinity prostacyclin binding sites in vascular tissue: radioligand studies with a chemically stable analogue. Biochem Pharmacol. 1983 Aug 15;32(16):2405–2410. doi: 10.1016/0006-2952(83)90683-4. [DOI] [PubMed] [Google Scholar]
  17. Stürzebecher S., Haberey M., Müller B., Schillinger E., Schröder G., Skuballa W., Stock G., Vorbrüggen H., Witt W. Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat. Prostaglandins. 1986 Jan;31(1):95–109. doi: 10.1016/0090-6980(86)90228-5. [DOI] [PubMed] [Google Scholar]
  18. Town M. H., Schillinger E., Speckenbach A., Prior G. Identification and characterisation of a prostacyclin-like receptor in bovine coronary arteries using a specific and stable prostacyclin analogue, ciloprost, as radioactive ligand. Prostaglandins. 1982 Jul;24(1):61–72. doi: 10.1016/0090-6980(82)90177-0. [DOI] [PubMed] [Google Scholar]
  19. Whittle B. J., Moncada S. Antithrombotic assessment and clinical potential of prostacyclin analogues. Prog Med Chem. 1984;21:237–279. doi: 10.1016/s0079-6468(08)70411-9. [DOI] [PubMed] [Google Scholar]
  20. Wilson N. H., Armstrong R. A., Jones R. L. Novel prostaglandin endoperoxide analogs having prostacyclin-like actions on platelets from human and horse but not from rat and rabbit. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:491–495. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES